Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses

Still listed by CMS but carries a termination date, so it is not valid for a current date of service.

Terminated with effect from 2024-12-12. First published 2023. CMS still lists this code in the current quarterly file - it carries a termination date rather than being removed.